Literature DB >> 16208494

Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand.

Yousef Najajreh1, Jana Kasparkova, Victoria Marini, Dan Gibson, Viktor Brabec.   

Abstract

trans-Diaminedicholoroplatinum(II) complexes with one planar and one non-planar heterocyclic amine ligand were designed as new potential antitumor drugs. The X-ray crystallographic structures of trans-[PtCl2(4-picoline)(piperidine)] and trans-[PtCl2(4-picoline)(piperazine)].HCl revealed that the piperidine and piperazine ligands bind to the platinum through the equatorial position and that the ligands adopt the chair conformation. The nonplatinated amine of the piperazine can form hydrogen bonds with atoms that are approximately 7.5 A away from the Pt binding site. DNA is considered a major pharmacological target of platinum compounds. Hence, to expand the database correlating structural features of platinum compounds and DNA distortions induced by these compounds, which may facilitate identification of more effective anticancer platinum drugs, we describe the DNA binding mode in a cell-free medium of trans-[PtCl2(4-picoline)(piperidine)] and trans-[PtCl2(4-picoline)(piperazine)].HCl. Interestingly, the overall impact of the replacement of the second ammine group in transplatin by the heterocyclic ligands appears to change the character of the global conformational changes induced in DNA towards that induced by cisplatin. The clinical ineffectiveness of the parent transplatin has been proposed to be also associated with its reduced capability to form bifunctional adducts in double-helical DNA. The results of the present work support the view that replacement of both ammine groups of transplatin by heterocyclic ligands enhances cytotoxicity probably due to the marked enhancement of the stability of intrastrand cross-links in double-helical DNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16208494     DOI: 10.1007/s00775-005-0024-2

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  29 in total

Review 1.  Current status of the development of trans-platinum antitumor drugs.

Authors:  J M Pérez; M A Fuertes; C Alonso; C Navarro-Ranninger
Journal:  Crit Rev Oncol Hematol       Date:  2000-08       Impact factor: 6.312

2.  DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].

Authors:  V Brabec; O Vrána; O Nováková; V Kleinwächter; F P Intini; M Coluccia; G Natile
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

3.  DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent.

Authors:  V Brabec; J Kaspárková; O Vrána; O Nováková; J W Cox; Y Qu; N Farrell
Journal:  Biochemistry       Date:  1999-05-25       Impact factor: 3.162

4.  Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies.

Authors:  J Kaspárková; K J Mellish; Y Qu; V Brabec; N Farrell
Journal:  Biochemistry       Date:  1996-12-24       Impact factor: 3.162

5.  Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.

Authors:  Tito Fojo; Nick Farrell; Waldo Ortuzar; Hideyuki Tanimura; John Weinstein; Timothy G Myers
Journal:  Crit Rev Oncol Hematol       Date:  2005-01       Impact factor: 6.312

6.  Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand. Mechanistic studies on antitumor action.

Authors:  Jana Kasparkova; Olga Novakova; Victoria Marini; Yousef Najajreh; Dan Gibson; Jose-Manuel Perez; Viktor Brabec
Journal:  J Biol Chem       Date:  2003-09-10       Impact factor: 5.157

7.  DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.

Authors:  Jana Kasparkova; Olga Novakova; Nicholas Farrell; Viktor Brabec
Journal:  Biochemistry       Date:  2003-01-28       Impact factor: 3.162

Review 8.  DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.

Authors:  Viktor Brabec
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2002

9.  DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)].

Authors:  A Zákovská; O Nováková; Z Balcarová; U Bierbach; N Farrell; V Brabec
Journal:  Eur J Biochem       Date:  1998-06-15

10.  Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding.

Authors:  V Brabec; J Reedijk; M Leng
Journal:  Biochemistry       Date:  1992-12-15       Impact factor: 3.162

View more
  5 in total

1.  Pt-bridges in various single-strand and double-helix DNA sequences. DFT and MP2 study of the cisplatin coordination with guanine, adenine, and cytosine.

Authors:  Matej Pavelka; Jaroslav V Burda
Journal:  J Mol Model       Date:  2006-09-20       Impact factor: 1.810

2.  Photocytotoxic trans-diam(m)ine platinum(IV) diazido complexes more potent than their cis isomers.

Authors:  Nicola J Farrer; Julie A Woods; Vivienne P Munk; Fiona S Mackay; Peter J Sadler
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

3.  Biophysical studies on the stability of DNA intrastrand cross-links of transplatin.

Authors:  Jana Kasparkova; Victoria Marini; Vendula Bursova; Viktor Brabec
Journal:  Biophys J       Date:  2008-08-01       Impact factor: 4.033

4.  DNA and glutathione interactions in cell-free media of asymmetric platinum(II) complexes cis- and trans-[PtCl2(isopropylamine)(1-methylimidazole)]: relations to their different antitumor effects.

Authors:  Tereza Suchánková; Marie Vojtísková; Jan Reedijk; Viktor Brabec; Jana Kaspárková
Journal:  J Biol Inorg Chem       Date:  2008-09-06       Impact factor: 3.358

5.  Comparison of the electronic properties, and thermodynamic and kinetic parameters of the aquation of selected platinum(II) derivatives with their anticancer IC50 indexes.

Authors:  Ondrej Bradác; Tomás Zimmermann; Jaroslav V Burda
Journal:  J Mol Model       Date:  2008-03-06       Impact factor: 1.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.